NASDAQ:AMYT

Amryt Pharma Competitors

$14.00
-0.04 (-0.28 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.81
Now: $14.00
$14.01
50-Day Range
$13.03
MA: $14.10
$14.74
52-Week Range
$10.06
Now: $14.00
$15.50
Volume7,822 shs
Average Volume21,075 shs
Market Capitalization$502.28 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Amryt Pharma (NASDAQ:AMYT) Vs. RVNC, DRNA, AXSM, NGM, MORF, and KURA

Should you be buying AMYT stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Amryt Pharma, including Revance Therapeutics (RVNC), Dicerna Pharmaceuticals (DRNA), Axsome Therapeutics (AXSM), NGM Biopharmaceuticals (NGM), Morphic (MORF), and Kura Oncology (KURA).

Revance Therapeutics (NASDAQ:RVNC) and Amryt Pharma (NASDAQ:AMYT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.

Insider & Institutional Ownership

74.4% of Revance Therapeutics shares are owned by institutional investors. Comparatively, 15.4% of Amryt Pharma shares are owned by institutional investors. 4.8% of Revance Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Revance Therapeutics and Amryt Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Revance Therapeutics-5,818.87%-85.72%-44.85%
Amryt PharmaN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and target prices for Revance Therapeutics and Amryt Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Revance Therapeutics00503.00
Amryt Pharma01302.75

Revance Therapeutics currently has a consensus price target of $36.40, suggesting a potential upside of 29.40%. Amryt Pharma has a consensus price target of $38.00, suggesting a potential upside of 171.43%. Given Amryt Pharma's higher possible upside, analysts plainly believe Amryt Pharma is more favorable than Revance Therapeutics.

Valuation & Earnings

This table compares Revance Therapeutics and Amryt Pharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revance Therapeutics$410,000.004,897.57$-159,430,000.00($3.67)-7.66
Amryt Pharma$58.12 million8.64$-30,854,220.00($0.86)-16.28

Amryt Pharma has higher revenue and earnings than Revance Therapeutics. Amryt Pharma is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Amryt Pharma beats Revance Therapeutics on 7 of the 13 factors compared between the two stocks.

Dicerna Pharmaceuticals (NASDAQ:DRNA) and Amryt Pharma (NASDAQ:AMYT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.

Insider & Institutional Ownership

80.6% of Dicerna Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.4% of Amryt Pharma shares are owned by institutional investors. 11.3% of Dicerna Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Dicerna Pharmaceuticals and Amryt Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dicerna Pharmaceuticals-88.81%-71.72%-16.60%
Amryt PharmaN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and target prices for Dicerna Pharmaceuticals and Amryt Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dicerna Pharmaceuticals00603.00
Amryt Pharma01302.75

Dicerna Pharmaceuticals currently has a consensus price target of $37.8333, suggesting a potential upside of 45.01%. Amryt Pharma has a consensus price target of $38.00, suggesting a potential upside of 171.43%. Given Amryt Pharma's higher possible upside, analysts plainly believe Amryt Pharma is more favorable than Dicerna Pharmaceuticals.

Valuation & Earnings

This table compares Dicerna Pharmaceuticals and Amryt Pharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dicerna Pharmaceuticals$23.90 million83.31$-120,460,000.00($1.76)-14.82
Amryt Pharma$58.12 million8.64$-30,854,220.00($0.86)-16.28

Amryt Pharma has higher revenue and earnings than Dicerna Pharmaceuticals. Amryt Pharma is trading at a lower price-to-earnings ratio than Dicerna Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Amryt Pharma beats Dicerna Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Axsome Therapeutics (NASDAQ:AXSM) and Amryt Pharma (NASDAQ:AMYT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.

Insider & Institutional Ownership

63.6% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 15.4% of Amryt Pharma shares are owned by institutional investors. 26.0% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Axsome Therapeutics and Amryt Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Axsome TherapeuticsN/A-62.33%-47.87%
Amryt PharmaN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and target prices for Axsome Therapeutics and Amryt Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Axsome Therapeutics101102.83
Amryt Pharma01302.75

Axsome Therapeutics currently has a consensus price target of $146.90, suggesting a potential upside of 177.22%. Amryt Pharma has a consensus price target of $38.00, suggesting a potential upside of 171.43%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than Amryt Pharma.

Valuation & Earnings

This table compares Axsome Therapeutics and Amryt Pharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axsome TherapeuticsN/AN/A$-68,350,000.00($2.01)-26.36
Amryt Pharma$58.12 million8.64$-30,854,220.00($0.86)-16.28

Amryt Pharma has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Amryt Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Amryt Pharma beats Axsome Therapeutics on 6 of the 11 factors compared between the two stocks.

NGM Biopharmaceuticals (NASDAQ:NGM) and Amryt Pharma (NASDAQ:AMYT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Insider and Institutional Ownership

49.6% of NGM Biopharmaceuticals shares are owned by institutional investors. Comparatively, 15.4% of Amryt Pharma shares are owned by institutional investors. 50.4% of NGM Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares NGM Biopharmaceuticals and Amryt Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NGM Biopharmaceuticals-91.64%-29.47%-25.58%
Amryt PharmaN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and price targets for NGM Biopharmaceuticals and Amryt Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NGM Biopharmaceuticals00523.29
Amryt Pharma01302.75

NGM Biopharmaceuticals currently has a consensus price target of $39.1111, suggesting a potential upside of 53.80%. Amryt Pharma has a consensus price target of $38.00, suggesting a potential upside of 171.43%. Given Amryt Pharma's higher possible upside, analysts plainly believe Amryt Pharma is more favorable than NGM Biopharmaceuticals.

Earnings and Valuation

This table compares NGM Biopharmaceuticals and Amryt Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NGM Biopharmaceuticals$103.54 million18.84$-42,790,000.00($0.85)-29.92
Amryt Pharma$58.12 million8.64$-30,854,220.00($0.86)-16.28

Amryt Pharma has lower revenue, but higher earnings than NGM Biopharmaceuticals. NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than Amryt Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

NGM Biopharmaceuticals beats Amryt Pharma on 8 of the 14 factors compared between the two stocks.

Morphic (NASDAQ:MORF) and Amryt Pharma (NASDAQ:AMYT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Insider and Institutional Ownership

61.5% of Morphic shares are owned by institutional investors. Comparatively, 15.4% of Amryt Pharma shares are owned by institutional investors. 39.5% of Morphic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Morphic and Amryt Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MorphicN/A-36.62%-20.69%
Amryt PharmaN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and price targets for Morphic and Amryt Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Morphic00203.00
Amryt Pharma01302.75

Morphic currently has a consensus price target of $63.3333, suggesting a potential upside of 6.71%. Amryt Pharma has a consensus price target of $38.00, suggesting a potential upside of 171.43%. Given Amryt Pharma's higher possible upside, analysts plainly believe Amryt Pharma is more favorable than Morphic.

Earnings and Valuation

This table compares Morphic and Amryt Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Morphic$16.98 million113.42$-43,330,000.00($2.69)-22.06
Amryt Pharma$58.12 million8.64$-30,854,220.00($0.86)-16.28

Amryt Pharma has higher revenue and earnings than Morphic. Morphic is trading at a lower price-to-earnings ratio than Amryt Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Amryt Pharma beats Morphic on 8 of the 12 factors compared between the two stocks.

Kura Oncology (NASDAQ:KURA) and Amryt Pharma (NASDAQ:AMYT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Insider and Institutional Ownership

94.7% of Kura Oncology shares are owned by institutional investors. Comparatively, 15.4% of Amryt Pharma shares are owned by institutional investors. 11.0% of Kura Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Kura Oncology and Amryt Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kura OncologyN/A-30.96%-28.02%
Amryt PharmaN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and price targets for Kura Oncology and Amryt Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kura Oncology011002.91
Amryt Pharma01302.75

Kura Oncology currently has a consensus price target of $39.5455, suggesting a potential upside of 38.42%. Amryt Pharma has a consensus price target of $38.00, suggesting a potential upside of 171.43%. Given Amryt Pharma's higher possible upside, analysts plainly believe Amryt Pharma is more favorable than Kura Oncology.

Earnings and Valuation

This table compares Kura Oncology and Amryt Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kura OncologyN/AN/A$-63,140,000.00($1.51)-18.92
Amryt Pharma$58.12 million8.64$-30,854,220.00($0.86)-16.28

Amryt Pharma has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Amryt Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Amryt Pharma beats Kura Oncology on 7 of the 11 factors compared between the two stocks.


Amryt Pharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13-1.4%$2.01 billion$410,000.00-6.12
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.09-1.3%$1.99 billion$23.90 million-16.20Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.99-2.1%$1.98 billionN/A-19.70
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.43-3.8%$1.95 billion$103.54 million-19.12Gap Down
MORF
Morphic
1.1$59.35-3.0%$1.93 billion$16.98 million-38.04Insider Selling
Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$28.57-0.8%$1.89 billionN/A-17.53
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.58-0.1%$1.88 billion$34.51 million-17.59News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02-0.4%$1.88 billionN/A-10.57
MacroGenics logo
MGNX
MacroGenics
1.2$31.16-1.3%$1.87 billion$64.19 million-9.96News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.96-2.7%$1.79 billion$1.63 billion14.54News Coverage
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.94-0.1%$1.77 billion$14.87 million-14.16News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$48.93-21.0%$1.72 billionN/A0.00Insider Buying
High Trading Volume
Gap Down
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.16-0.1%$1.72 billion$26.87 million-12.65
FibroGen logo
FGEN
FibroGen
1.8$18.57-1.3%$1.70 billion$256.58 million-7.11Analyst Downgrade
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$41.57-1.3%$1.66 billionN/A-173.21
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.99-7.6%$1.65 billion$2.34 million-10.17Gap Down
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.15-1.2%$1.65 billionN/A-6.46Insider Selling
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$35.26-6.0%$1.64 billionN/A0.00Insider Selling
News Coverage
Gap Down
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.19-1.5%$1.64 billion$428.41 million14.77
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.80-1.3%$1.63 billion$320,000.00-8.71Analyst Report
News Coverage
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.32-0.2%$1.61 billionN/A0.00
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.61-1.4%$1.55 billion$175.34 million-15.06
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.8$37.41-13.5%$1.54 billionN/A0.00Insider Selling
Gap Down
Generation Bio logo
GBIO
Generation Bio
1.8$27.20-5.3%$1.53 billionN/A0.00Insider Selling
News Coverage
Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$27.28-0.3%$1.53 billionN/A0.00Lockup Expiration
News Coverage
uniQure logo
QURE
uniQure
1.7$33.74-5.2%$1.52 billion$7.28 million-8.95Gap Down
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.60-4.0%$1.52 billion$145.97 million-6.72News Coverage
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.56-3.8%$1.51 billion$82.27 million-18.44Unusual Options Activity
News Coverage
Gap Down
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$28.96-0.4%$1.50 billion$4.23 million-21.45
ATBPD
Antibe Therapeutics
0.1$3.88-0.5%$1.50 billion$7.51 million-6.46Gap Down
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$28.31-0.7%$1.50 billion$392.76 million11.75Analyst Revision
News Coverage
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$33.30-2.3%$1.49 billionN/A0.00Insider Selling
News Coverage
Gap Down
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$29.19-5.9%$1.46 billion$19.89 million-13.77Unusual Options Activity
News Coverage
Gap Up
Zymeworks logo
ZYME
Zymeworks
1.8$31.00-1.5%$1.43 billion$29.54 million-8.22News Coverage
Endo International logo
ENDP
Endo International
1.3$6.20-1.0%$1.43 billion$2.91 billion-9.12Analyst Report
News Coverage
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.80-1.5%$1.42 billion$6.20 million-14.39News Coverage
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$60.16-4.3%$1.40 billionN/A0.00Gap Down
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$20.95-3.9%$1.37 billion$73.41 million-4.43Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$26.62-3.5%$1.33 billionN/A-2.88Gap Down
OLMA
Olema Pharmaceuticals
1.6$32.84-0.4%$1.32 billionN/A0.00
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$35.80-3.8%$1.31 billionN/A0.00Gap Down
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$34.35-2.6%$1.26 billionN/A-19.08News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.51-1.3%$1.26 billion$4.23 million-9.22Gap Down
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$33.90-7.8%$1.21 billion$57.05 million0.00Gap Down
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$17.69-2.5%$1.21 billionN/A-7.46
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$38.49-0.2%$1.21 billionN/A-2.75Insider Selling
News Coverage
Innoviva logo
INVA
Innoviva
1.4$11.70-1.6%$1.19 billion$261.02 million5.97
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.39-2.9%$1.18 billion$59.70 million-193.90Unusual Options Activity
Gap Down
Shattuck Labs logo
STTK
Shattuck Labs
1.4$28.23-3.0%$1.18 billionN/A0.00Lockup Expiration
Gap Up
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.